CN201
- Generic Name
- CN201
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- MSD R&D (China) Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06189391
- Locations
- 🇨🇳
Fifth Medical Center of PLA General Hospital ( Site 0005), Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Xiamen University ( Site 0011), Xiameng, Fujian, China
🇨🇳Beijing Cancer hospital ( Site 0001), Beijing, Beijing, China
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- MSD R&D (China) Co., Ltd.
- Target Recruit Count
- 203
- Registration Number
- NCT05579132
- Locations
- 🇨🇳
The Second Affiliated Hospital of Third Military Medical University ( Site 0008), Chongqing, Chongqing, China
🇨🇳Southern Medical University Nanfang Hospital ( Site 0004), Guangzhou, Guangdong, China
🇨🇳The Second Hospital of Hebei Medical University ( Site 0003), Shijiazhuang, Hebei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath